News & Events

• FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
  Published on 2024-12-09
• Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
  Published on 2024-11-22
• Publication of Q3 Interim Report January – September 2024
  Published on 2024-11-15
• Genetic Analysis AS: Interim report January – September 2024
  Published on 2024-11-15
• Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
  Published on 2024-11-13
• Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
  Published on 2024-11-06
• Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
  Published on 2024-10-16
• Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
  Published on 2024-09-30
• Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
  Published on 2024-09-26
• Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
  Published on 2024-09-13
• Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
  Published on 2024-09-12
• Publication of Half-year report 2024
  Published on 2024-08-30
• Genetic Analysis AS: Publication of Half-year report 2024
  Published on 2024-08-30
• Genetic Analysis AS launches the GA-map® Discovery reagent kit – a precision microbiome research assay
  Published on 2024-08-15
• Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises
  Published on 2024-08-14